Evidence map›Paper›PMID 39269284›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort Study.

Kamaria L Lee, Varada Sarovar, Jennifer O Lam, Wendy A Leyden, Stacey E Alexeeff, Alexandra N Lea, Rulin C Hechter, Haihong Hu, Julia L Marcus, Qing Yuan and 6 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kamaria L LeeDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-5552-5988
Varada SarovarDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0009-0005-1860-5133
Jennifer O LamDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0000-0001-5650-4310
Wendy A LeydenDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0009-0003-8916-596X
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0000-0001-8988-6976
Alexandra N LeaDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0000-0001-6194-699X
Rulin C HechterDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.ORCID 0000-0001-8684-6506
Haihong HuMid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Washington, DC.ORCID 0000-0002-8396-4467
Julia L MarcusDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.ORCID 0000-0002-8552-414X
Qing YuanDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.ORCID 0009-0001-5206-9910
Jennifer R KramerCenter for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.ORCID 0000-0003-2953-4949
Lilie L LinDivision of Radiation Oncology, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7681-8966
Elizabeth Y ChiaoDivision of Cancer Prevention and Population Sciences, Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5752-2916
William J TownerDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.ORCID 0000-0001-5645-2979
Michael A HorbergDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.ORCID 0000-0002-6971-7646
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Pleasanton, California.ORCID 0000-0001-9322-1395

Funding

(PQ3) Addressing Cancer Treatment Disparities for Persons with HIVR01CA260689 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHIAO, ELIZABETH Y., SILVERBERG, MICHAEL J · 2021 to 2025
$4.0M
Electronic Health Record-Based Dementia Prediction for HIV Primary CareK01AI157849 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI LAM, JENNIFER · 2021 to 2025
$713k
Gilead Sciences (Gilead)National Cancer Institute (NCI) R01CA260689National Institute of Allergy and Infectious Diseases (NIAID) K01AI157849NCI NIH HHS R01 CA260689NIAID NIH HHS K01 AI157849
6 · The paper itself

Abstract

backgroundWith extended lifespans for people with human immunodeficiency virus (PWH), there is a corresponding increased burden of chronic illnesses, including cancer. Our objective was to estimate the excess mortality among PWH with cancer compared with people without HIV (PWoH), accounting for the higher background mortality in the general PWH population.

methodsWe identified 39,000 PWH and 387,767 demographically matched PWoH in three integrated healthcare systems from 2000 to 2016. We estimated excess mortality among PWH with cancer, computed as the cancer mortality rate difference-in-difference comparing PWH and PWoH. We evaluated five cancer groups: any cancer; virus-, human papillomavirus-, and Epstein-Barr virus -related cancers; virus-unrelated cancers, and common individual cancers. We fitted a multivariable additive Poisson model to estimate excess mortality among PWH with cancer.

resultsPWH with any cancer had excess mortality compared with PWoH [41.3/1,000 person-years (py), 95% confidence interval (CI), 34.0-48.7]. The highest excess mortality was observed for Epstein-Barr virus-related cancers (63.2/1,000 py, 95% CI, 47.8-78.7), lung cancer (147.7/1,000 py, 95% CI, 41.1-254.3), and non-Hodgkin lymphoma (70.5/1,000 py, 95% CI, 51.4-89.6). Excess mortality among PWH was attenuated from 2009 to 2016, and PWH with cancer had no excess mortality 5 years after diagnosis.

conclusionPWH in care may have excess mortality from certain cancer types, although disparities may have attenuated over time and do not persist beyond 5 years after diagnosis. IMPACT: Findings may guide improved clinical practice and suggest further research is needed to investigate whether cancer treatment or other factors contribute to mortality disparities for PWH with cancer.

Indexed as

HIV InfectionsNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID39269284
PMCPMC11611626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.